Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Savaysa Shows The Good And Bad Of Being Late In Class

Apr 27 2015

• By Sue Sutter

Related Content

Edoxaban Review ‘Not About Comparative Efficacy,’ FDA Says

Nov 10 2014

<em>Xarelto</em> Tested FDA’s Comparative Efficacy Powers, But Conservative View Prevailed

May 01 2012

Bayer/J&J's Xarelto Gets Advisory Cmte. Endorsement In A-Fib, But Not First-Line Use

Sep 08 2011

<em>Savaysa</em> Clinical Development

Apr 27 2015

<em>Savaysa</em> Under-Dosing Not A Concern In DVT/PE Treatment

Apr 20 2015

<em>Savaysa</em> A-Fib Data Led To Conflicting FDA Views On Dose, Population

Apr 20 2015

Related Companies

Orphan Disease Treatment Institute Co., Ltd.

Boehringer Ingelheim GmbH

Johnson & Johnson

Bayer AG

Bristol Myers Squibb Company

Pfizer Inc.

Additional Topics

United States BioPharmaceutical

More from United States

More from North America

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window